Reference is made to the stock exchange announcement by SoftOx Solutions AS (the
"Company") published on 15 December 2021 regarding the successfully completed
private placement of approximately NOK 50 million through the issue of new
shares in the Company at a subscription price of NOK 55 per share (the "Private
Placement"). In the announcement it was expressed that the Company would
consider undertaking a subsequent offering of up to 218,000 new shares at the
same subscription price as in the Private Placement, depending on the
development of the price of the shares in the Company after completion of the
Private Placement.
 
The board of directors has resolved not to proceed with the Subsequent Offering.
Following announcement of the Private Placement, the Company's shares have
traded around or below the subscription price in the Private Placement.
Accordingly, any shareholder wishing to reduce the dilutive effect of the
Private Placement have had the opportunity to purchase shares in the Company in
the market at prices similar to or below what would have been the subscription
price in the Subsequent Offering.


For further information, please contact:

CEO Geir Almås of SoftOx Solutions AS, or
CFO Kristine Rød of SoftOx Solutions AS
Mail: ir@soft-ox.com
Mobile: (+47) 948 59 599

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian
BioTech company based in Oslo with the aim of helping to combat major threats to
human health, namely the emergence of antimicrobial resistance (AMR), biofilm
infections in chronic wounds and the spread of viruses. For more information on
SoftOx, visit www.soft-ox.com